

## ● NATIONAL FUNDING/ACCESS DECISIONS

### LUTIGEST<sup>®</sup>

#### Scottish Medicines Consortium (SMC) decisions

The *Scottish Medicines Consortium* has advised (October 2016) that progesterone (*Lutigest*<sup>®</sup>) is accepted for use within NHS Scotland for luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women. This advice is contingent upon the continuing availability of the Patient Access Scheme (PAS) in NHS Scotland or a list price that is equivalent or lower.

### LUBION<sup>®</sup>

#### Scottish Medicines Consortium (SMC) decisions

SMC No. SMC2017

The *Scottish Medicines Consortium* has advised (July 2018) that progesterone (*Lubion*<sup>®</sup>) is accepted for use within NHS Scotland for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.

### UTROGESTAN<sup>®</sup> VAGINAL CAPSULES

#### Scottish Medicines Consortium (SMC) decisions

The *Scottish Medicines Consortium* has advised (May 2017) that micronised progesterone (*Utrogestan Vaginal*<sup>®</sup>) is accepted for use within NHS Scotland for supplementation of the luteal phase during Assisted Reproductive Technology cycles in women. This advice is contingent upon the continuing availability of the Patient Access Scheme in Scotland or a list price that is equivalent or lower.

## ● LESS SUITABLE FOR PRESCRIBING

- With vaginal use Progesterone pessaries are less suitable for prescribing.

## ● MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

### Pessary

#### ► *Cyclogest* (L.D. Collins & Co. Ltd)

**Progesterone 200 mg** Cyclogest 200mg pessaries | 15 pessary [PoM] £8.95 DT = £8.95

**Progesterone 400 mg** Cyclogest 400mg pessaries | 15 pessary [PoM] £12.96 DT = £12.96

#### ► *Lutigest* (Ferring Pharmaceuticals Ltd)

**Progesterone 100 mg** Lutigest 100mg vaginal tablets | 21 pessary [PoM] £19.50 DT = £19.50

### Vaginal gel

#### ► *Crinone* (Merck Serono Ltd)

**Progesterone 80 mg per 1 gram** Crinone 8% progesterone vaginal gel | 15 unit dose [PoM] £30.83 DT = £30.83

### Capsule

EXCIPIENTS: May contain Arachis (peanut) oil

#### ► *Utrogestan* (Besins Healthcare (UK) Ltd)

**Progesterone 100 mg** Utrogestan 100mg capsules | 30 capsule [PoM] £5.13 DT = £5.13

**Progesterone 200 mg** Utrogestan 200mg vaginal capsules with applicators | 21 capsule [PoM] £21.00 DT = £21.00

## 8.1a Anti-oestrogens

### OVULATION STIMULANTS

#### Clomifene citrate

20-Nov-2019

#### (Clomiphene citrate)

- DRUG ACTION** Anti-oestrogen which induces gonadotrophin release by occupying oestrogen receptors in the hypothalamus, thereby interfering with feedback mechanisms; chorionic gonadotrophin is sometimes used as an adjunct.

#### ● INDICATIONS AND DOSE

##### Male infertility due to ovulatory dysfunction

##### ► BY MOUTH

- Adult (female): 50 mg once daily for 5 days, to be started at any time if no recent uterine bleeding or on or around the fifth day of cycle if progesterone-induced bleeding is planned or if spontaneous uterine bleeding occurs, then 100 mg once daily if required for 5 days, this second course to be given at least 30 days after the first course, only in the absence of ovulation; most patients who are going to respond will do so to first course, 3 courses should constitute adequate therapeutic trial; long-term cyclical therapy not recommended (beyond a total of 6 cycles).

#### IMPORTANT SAFETY INFORMATION

Manufacturer advises clomifene should not normally be used for longer than 6 cycles (possible increased risk of ovarian cancer).

- CONTRA-INDICATIONS** Abnormal uterine bleeding of undetermined cause · hormone-dependent tumours · ovarian cysts
- CAUTIONS** Ectopic pregnancy · incidence of multiple births increased (consider ultrasound monitoring) · ovarian hyperstimulation syndrome · polycystic ovary syndrome (cysts may enlarge during treatment, also risk of exaggerated response to usual doses) · uterine fibroids
- SIDE-EFFECTS** Abdominal distension · alopecia · angioedema · anxiety · breast tenderness · cataract · cerebral thrombosis · depression · disorientation · dizziness · fatigue · headache · hot flush · hypertriglyceridaemia · insomnia · jaundice cholestatic · menstrual cycle irregularities · mood altered · nausea · neoplasms · nervous system disorders · optic neuritis · ovarian and fallopian tube disorders · palpitations · pancreatitis · paraesthesia · psychosis · seizure · skin reactions · speech disorder · stroke · syncope · tachycardia · uterine disorders · vertigo · vision disorders · visual impairment (discontinue and initiate ophthalmological examination) · vomiting
- CONCEPTION AND CONTRACEPTION** Exclude pregnancy before treatment.
- PREGNANCY** Possible effects on fetal development.
- BREAST FEEDING** May inhibit lactation.
- HEPATIC IMPAIRMENT** Manufacturer advises avoid in liver disease or history of liver dysfunction.
- PATIENT AND CARER ADVICE**  
**Conception and contraception** Patients planning to conceive should be warned that there is a risk of multiple pregnancy (rarely more than twins).